EN | |

BOKANGTAI®(Mitiglinide Tablets)

A prescription oral drug for the treatment of Type 2 diabetes

Bokangtai(Mitiglinide) is a new, potentially best-in-class oral anti-diabetic agent which belongs to the glinides class of blood glucose lowering compounds. It has been shown to improve postprandial hyperglycemia in patients with Type 2 diabetes and has received New Drug Approval as a first and/or second line of treatment for the disease from the China Food and Drug Administration.

Mitiglinide highlights :

Class B in NRDL, the first tier for hypoglycemic agent

Mitiglinide is potentially best-in-class with key clinical advantages

In clinical studies, Mitiglinide demonstrated a fast onset of action and was shown to be safe and effective with reduced gastrointestinal and cardiovascular side effects compared to other treatments in the same class

Mitiglinide is an insulinotropic agent that plays a major role in Type 2 Diabetes treatment

Uni-Bio Science acquired exclusive rights to distribute and commercialise Mitiglinide globally from Jiangsu Hansoh Pharmaceutical Co. Ltd in November 2014

Mitiglinide is potentially best-in-class with key clinical advantages.

Mitiglinide softens existing drawbacks of other glinides

- Stronger affinity for SUR1 in pancreatic B-cells

- Less GI and cardiovascular side effects

Mitiglinide strengthens existing advantages of glinides

- Improve dyslipidemia condition

- Lower risk of post prandial hypoglycaemia (suitable for eldery)